RIGL — Rigel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $241.05m
- $251.64m
- $116.88m
- 36
- 56
- 58
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -66.9 | -29.7 | -17.9 | -58.6 | -25.1 |
Depreciation | |||||
Non-Cash Items | 8.04 | 7.17 | 12.9 | 12.9 | 8.59 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 16.7 | -30.3 | 9.72 | -29 | 9.52 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -41.5 | -52.2 | 5.88 | -73.8 | -5.74 |
Capital Expenditures | -1.46 | -1.26 | -0.627 | -0.45 | -15 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -22.2 | 48.7 | -79.4 | 73.2 | 10.7 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -23.7 | 47.5 | -80 | 72.8 | -4.3 |
Financing Cash Flow Items | — | — | 57.9 | -15.1 | -2.63 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 11.4 | 12.6 | 62.7 | 6.55 | 18.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -53.8 | 7.85 | -11.5 | 5.57 | 8.33 |